25 years of aripiprazole: Emergence, evolution & reappraisal

Read full text Summarise with VIRAT
Authors: Jyothsna Kuralla
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Aripiprazole, introduced 25 years ago, represents a major shift in antipsychotic pharmacotherapy through its pioneering mechanism of dopamine D₂ partial agonism. Unlike traditional first- and second-generation antipsychotics that rely primarily on D₂ antagonism, aripiprazole functions as a dopamine–serotonin stabilizer, modulating neurotransmission in both hyper- and hypodopaminergic states. This mechanism—supported by functional selectivity at D₂ and 5-HT receptors—provides effective control of positive, negative, and mood symptoms while reducing the risks of extrapyramidal symptoms, prolactin elevation, and metabolic disturbances. Over its clinical lifespan, aripiprazole has demonstrated broad efficacy as monotherapy for schizophrenia, bipolar I disorder, irritability associated with autism spectrum disorder, and Tourette’s disorder. Its versatility extends beyond monotherapy, with strong evidence for reversing antipsychotic-induced hyperprolactinaemia, augmenting clozapine in treatment-resistant schizophrenia, enhancing the effects of mood stabilizers in bipolar disorder, and serving as a robust augmentation strategy in treatment-resistant depression. Adjunctive use also shows potential for mitigating olanzapine-associated metabolic effects. Long-acting injectable formulations further support adherence and relapse prevention. After 25 years, aripiprazole remains a uniquely adaptable therapeutic option, exemplifying the clinical advantages of receptor modulation over antagonism and continuing to influence the evolution of next-generation antipsychotic development.

Fields of Study & Subjects

Schizophrenia research and treatment Neurotransmitter Receptor Influence on Behavior Treatment of Major Depression

Publication details

Journal / source
International Journal of Pharmacology and Clinical Research
Volume
8
Issue
3
Pages
149–152
Publication date
1 March 2026
Language
EN